Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Free Cash Flow (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Free Cash Flow data on record, last reported at -$12.1 million in Q1 2026.

  • On a quarterly basis, Free Cash Flow fell 192.93% to -$12.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$35.7 million, a 84.26% decrease, with the full-year FY2025 number at -$27.8 million, down 45.18% from a year prior.
  • Free Cash Flow reached -$12.1 million in Q1 2026 per IKT's latest filing, down from -$7.5 million in the prior quarter.
  • Over the last five years, Free Cash Flow for IKT hit a ceiling of -$3.4 million in Q4 2023 and a floor of -$12.1 million in Q1 2026.
  • A 5-year average of -$5.6 million and a median of -$4.9 million in 2024 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: soared 35.25% in 2024, then tumbled 192.93% in 2026.
  • Tracing IKT's Free Cash Flow over 5 years: stood at -$3.6 million in 2022, then rose by 3.2% to -$3.4 million in 2023, then plummeted by 55.28% to -$5.3 million in 2024, then plummeted by 40.6% to -$7.5 million in 2025, then plummeted by 60.45% to -$12.1 million in 2026.
  • Business Quant data shows Free Cash Flow for IKT at -$12.1 million in Q1 2026, -$7.5 million in Q4 2025, and -$10.6 million in Q3 2025.